Tag Archives: Phil Nadeau

Chimerix (CMRX) Receives a Hold from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Chimerix (NASDAQ: CMRX), with a price target of $6. The company’s shares opened today at $3.55, close to its 52-week low of $3.53. According

Cowen & Co. Sticks to Its Buy Rating for Epizyme (EPZM)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $11.45. According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.2% and a 56.4% success

Cowen & Co. Maintains Their Hold Rating on Regeneron (REGN)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Regeneron (NASDAQ: REGN) today and set a price target of $385. The company’s shares opened today at $364.48. According to TipRanks.com, Nadeau is a 5-star analyst with an average

Kezar Life Sciences Inc (KZR) Received its Third Buy in a Row

After William Blair and Wells Fargo gave Kezar Life Sciences Inc (NASDAQ: KZR) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau maintained a Buy rating on Kezar Life Sciences

Analysts Offer Insights on Healthcare Companies: Portola Pharma (NASDAQ: PTLA), Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) and Loxo Oncology (NASDAQ: LOXO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Portola Pharma (NASDAQ:PTLA), Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) and Loxo Oncology (NASDAQ:LOXO) with bullish sentiments. Portola Pharma (PTLA) In a report released today,

Cowen & Co. Keeps Their Buy Rating on Acorda Therapeutics (ACOR)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Acorda Therapeutics (NASDAQ: ACOR) today and set a price target of $30. The company’s shares opened today at $27.50. According to TipRanks.com, Nadeau is a 5-star analyst with an